Patent · US Expired

Compositions and methods for inhibiting thrombogenesis

US6001820A · kind A · utility

31Cited by
21References
45Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 6, 1997
Grant dateDec 14, 1999
Priority date
Expiry dateJun 6, 2017

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61L33/08
  • WIPO fieldMedical technology
  • WIPO sectorInstruments

Abstract

The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) selectively inactivating thrombin which is bound either to fibrin in a clot or to some other surface, but which has only minimal inhibitory activity against free thrombin, i.e., fluid-phase thrombin; (2) inhibiting the assembly of the intrinsic tenase complex, thereby inhibiting the activation of Factor X by Factor IXa; and (3) inhibiting the activation of Factor IX by Factor XIa. The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.